ADA and severe combined immunodeficiency: Gene therapy did not achieve clinical success until the early 1990s, French Anderson and colleagues utilized ex vivo gene therapy for patients with adenosine deaminase deficiency severe combined immunodeficiency (ADA-SCID) by administering injections of T cells transformed by recombinant retroviruses carrying the ADA.